Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yea Nanologix must have gone to the corner drug store and picked up this strain of Ecoli to test!
It would not be the first time they misworded An update but I do not doubt that they (Battelle) are testing it with NNLX products. The way you posted this leads me to believe that you are saying the company is misleading it investors. Strong words but at least you covered your back side by saying it your oppinion!
Andre
Battelle manages the National Biodefense Analysis and Countermeasures Center
the ASM meeting is for Biodefense and emerging diseases
Anthrax and the blubonic plague test were done by Battelle (assumed)
Anthrax and Blubonic plague could be used as major biologcal weapons.
From NNLX
<<<Without treatment, the mortality rate for Y. pestis is about 50-90 percent. However, the rate is cut to appoximately 1-15 percent with treatment. This makes the rapid detection and identification of Yersinia pestis critical in providing effective treatment and homeland security protection.>>>
The purpose of the meeting is Organizations around the world are involved in research pertaining to biothreat agents, vaccines, detection and diagnostic procedures, animal and plant pathogens, biosecurity facilities, global surveillance, the training of individuals in BL3 and BL4 labs, and other vital topics. As technology changes and research evolves, professionals involved in biodefense are being challenged to move ever faster to respond to the growing threat of bioterrorism. ASM offers the Biodefense and Emerging Diseases Research Meeting as an opportunity for addressing these needs.
Battelle is the government's proxy
Battelle is doing the testing
Nanologix has what they are looking for.
Andre
" expedite collaboration, and speed commercialization of technology"
I feel that since this new finding in December we have kicked into a higher gear and we are closer to commercialization.
Andre
Battelle (did)is doing the testing for TB, gram negitive, and gram positive bacteria. They are probable also doing the Anthrax and the Blubonic plague testing as well and if you did not know Battelle is managing the government biodefense lab. http://battelle.org/LABMANAGEMENT/nbacc.aspx
Andre
You are right they are no Corning but......
What if you look at the company from A different perspective such as an IP type of company where NNLX licences out its kits and collects royalties or X amount per kit from a third party(ies) most of that money will go directly to the bottom line over head would be minimal. So I feel if that is the route taken 40% is very realistic if not maybe even on the low side.
Andre
Yea sorry its Monday morning. I tryed to delete my message but it wouldn't let me.
Happy Monday!
Capitalismforever
I think this is something(maybe) new you just posted
From your second link "aculture medium" perhaps has to do with Listeria!
"(a)Identification. A selective culture medium is a device that consists primarily of liquid or solid biological materials intended for medical purposes to cultivate and identify certain pathogenic microorganisms. The device contains one or more components that suppress the growth of certain microorganisms while either promoting or not affecting the growth of other microorganisms. The device aids in the diagnosis of disease caused by pathogenic microorganisms and also provides epidemiological information on these diseases.
Andre
on the second link click on Regulation Number: 866.2360
mo-john
Why don't you have the lab that is doing the tests call nnlx directly and ask them. That way they can answer any other questions that they may have. If this lab has their product i'm sure they would be more than happy to guide them to sucsess with their testing.
Andre
Rail
<<<going off heresay...>>>
Exactly !!!!!!
Before I sell my shares I want to hear what the Largest hospital group in the world, who before taking on this clinical trial worked with the products for at least 9 months, has to say about the trial results. I will not sell shares based on some guy who stayed at a Holiday Inn Express.
Andre
EMPT
Here is another one for you. I think this is the BNC (not 100% sure). Again this is from there patents page 4.
[0008]This invention differs from other rapid micromethods by utilizing a unique sampling detection unit, comprised of an array of long, parallel, similarly shaped and sized open-ended micro-channels for retaining the products of enzyme-substrate reactions from at least one single trapped cell. The processes of sampling and sample treatment occur in the same device. The device allows for the detection, identification and enumeration of single entities within the SDU with the use of fluorescent or light microscopes or other simple optical devices or automated instruments for microanalysis
[0014]The addition of an artificial substrate to the micro-channels can be repeated a plurality of times on the micro-channel plate to obtain enzymatic profiles to identify a plurality of species of microorganisms from one sample.
As 0014 above points out it can identify different species from one sample. Maybe that poster should not listen to his friend from the AXK board who supposedly "tested" NNLX products.
Keep in mind when a sample is sent to a lab that lab is not testing for all existing bacteria.
For future reference if you are going to repost someone's post it would be appropriate to identify that poster to give that person credit for the post.
That being said who do you believe TMC or annonomous poster on yahoo?
Here is a link to their patents. There are 4 of them at top of page you can go between the different ones.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=nanologix.AS.&OS=AN/nanologix
[0014]In another embodiment, there is provided a method for the rapid detection, identification and/or enumeration of one or more live target microorganisms, such as bacteria, yeast fungi or eukaryotic cells, in a liquid sample. The method comprises placing a permeable membrane having at least one type of immobilized antibody thereon specific to an antigen on or in a liquid sample which may contain at least one live target microorganism so as to form at least one target microorganism antigen-antibody complex. Any non-bound microorganisms are washed away from the permeable membrane. The microorganism antigen-antibody complex(es) is incubated for a period of time to form at least one microcolony on the permeable membrane. The microcolony(ies) on the permeable membrane then is stained by placing the permeable membrane on a plate containing, for example, agar, and at least one chromogenic substrate, at least one fluorogenic substrate or a combination of the two dissolved therein to obtain colored and/or fluorescent spots of the target microorganism(s).
Read the above than read what that poster wrote. I am no microbiologist but what he is saying and what it says don't jive.
So I don't know about you but I will believe The patent and TMC and Battelle how about you?
Andre
Mo-john
What is your background and what type of tests are you running. TIA
Andre
as of June 2010
109,374,822 share outstanding
http://www.nanologix.com/includes/Financials_June_30_2010.pdf
Andre
SM
You counldn't be more wrong!
Step back and look at the big picture and see what is going on.
TMC is the largest hospital group in the world. They want this product (they are paying for the clinical trial). They need this product (cost savings and life savings). THe reuters video PR yesterday, do you think that was from out of the blue? This is part of a concerted effort to create a BUZZ about the product and about the clinical trial you will see more and more exposure of the two (see the rail splitter's post on yahoo board) leading up to the ASM meeting where they can show the world what they were able to do in conjuction with these products. It is a big show which will lead to research dollars. This will be over a buck come summer.IMHO
Andre
You are forgetting one thing.
The kuwait company.
http://www.amgkwt.com/home.html
There is no tell how fast thing will move in the middle east. I am willing to bet it will move a lot quicker than when Bret built the Hubbard clean room. A partner with a cutomer pipeline already in place should help ramp up sales quickly. The part that I don't know is how long for approval in those countries.
Andre
My bad! the CE mark is for the EU not middle east and africa. I guess I am too excited about the global expantion.
In order to sell to the EU a company must partner with existing companies and must obtained A CE stamp of approval. Here is a post with a link that I had posted on another board in November kind of explains whagts happening.
In order to sell a medical device in the EU NNLX will need to obtain a CE certification. I am wondering if they are working on this now perhaps with
These guys
http://www.amgkwt.com/home.html
The Authorized Representative
An Authorized Representative (AR) is an entity appointed by the manufacturer and delegated to act on their behalf to carry out certain tasks required by the medical device Directives. The AR must be established inside the European Union and be available to Member State Authorities. The manufacturer, however, remains ultimately responsible for the actions carried out by the AR.
The Directives require that the AR be listed on the device label or packaging, in the Instructions For Use and on the Declaration of Conformity. In addition, the AR keeps the Technical File available for review by Competent Authorities, and plays an essential role in the post-market surveillance and vigilance system
http://www.emergogroup.com/articles/who-needs-ce-mark
Andre
UTHSC Houston will evaluate the test kits on MRSA and Pseudomonas
It appears they are confident that these test kits will reduce time to result s. Both of these bacteria groups are major problems to hospitals. Here is a little info on Pseudomonas.
Multi-drug resistant Pseudomonas is one of the most serious and difficult hospital-acquired infections to treat and affects patients with ventilator-associated pneumonia, cystic fibrosis, low white cell counts, burns and diabetic ulcers.
The overall mortality associated with Pseudomonas aeruginosa bacteremia is about 50 percent.
http://www.phageinternational.com/pathogens/pseudomonas.htm
Of the 2 million nosocomial infections each year, 10% are caused by P. aeruginosa. The bacterium is the second most common cause of nosocomial pneumonia and the most common cause of intensive care unit (ICU) pneumonia. Pseudomonas infections can be spread within hospitals by health care workers, medical equipment, sinks, disinfectant solutions, and food. These infections area very serious problem in hospitals for two reasons. First, patients who arecritically ill can die from a pseudomonas infection. Second, many Pseudomonas bacteria are resistant to certain antibiotics, which makes them difficult to treat.
Read more: Pseudomonas infections, Information about Pseudomonas infections http://www.faqs.org/health/topics/52/Pseudomonas-infections.html#ixzz18TupvT4h
The genus Pseudomonas contains more than 140 species, most of which are saprophytic. More than 25 species are associated with humans. Most pseudomonads known to cause disease in humans are associated with opportunistic infections. These include P aeruginosa, P fluorescens, P putida, P cepacia, P stutzeri, P maltophilia, and P putrefaciens. Only two species, P mallei and P pseudomallei, produce specific human diseases: glanders and melioidosis. Pseudomonas aeruginosa and P maltophilia account for approximately 80 percent of pseudomonads recovered from clinical specimens. Because of the frequency with which it is involved in human disease, P aeruginosa has received the most attention. It is a ubiquitous free-living bacterium and is found in most moist environments. Although it seldom causes disease in healthy individuals, it is a major threat to hospitalized patients, particularly those with serious underlying diseases such as cancer and burns. The high mortality associated with these infections is due to a combination of weakened host defenses, bacterial resistance to antibiotics, and the production of extracellular bacterial enzymes and toxins.
http://www.phageinternational.com/pathogens/pseudomonas.htm